We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models.
- Authors
Smolle, Maria Anna; van de Sande, Michiel; Callegaro, Dario; Wunder, Jay; Hayes, Andrew; Leitner, Lukas; Bergovec, Marko; Tunn, Per-Ulf; van Praag, Veroniek; Fiocco, Marta; Panotopoulos, Joannis; Willegger, Madeleine; Windhager, Reinhard; Dijkstra, Sander P. D.; van Houdt, Winan J.; Riedl, Jakob M.; Stotz, Michael; Gerger, Armin; Pichler, Martin; Stöger, Herbert
- Abstract
Currently, patients with extremity soft tissue sarcoma (eSTS) who have undergone curative resection are followed up by a heuristic approach, not covering individual patient risks. The aim of this study was to develop two flexible parametric competing risk regression models (FPCRRMs) for local recurrence (LR) and distant metastasis (DM), aiming at providing guidance on how to individually follow-up patients. Three thousand sixteen patients (1931 test, 1085 validation cohort) with high-grade eSTS were included in this retrospective, multicenter study. Histology (9 categories), grading (time-varying covariate), gender, age, tumor size, margins, (neo)adjuvant radiotherapy (RTX), and neoadjuvant chemotherapy (CTX) were used in the FPCRRMs and performance tested with Harrell-C-index. Median follow-up was 50 months (interquartile range: 23.3–95 months). Two hundred forty-two (12.5%) and 603 (31.2%) of test cohort patients developed LR and DM. Factors significantly associated with LR were gender, size, histology, neo- and adjuvant RTX, and margins. Parameters associated with DM were margins, grading, gender, size, histology, and neoadjuvant RTX. C-statistics was computed for internal (C-index for LR: 0.705, for DM: 0.723) and external cohort (C-index for LR: 0.683, for DM: 0.772). Depending on clinical, pathological, and patient-related parameters, LR- and DM-risks vary. With the present model, implemented in the updated Personalised Sarcoma Care (PERSARC)-app, more individualized prediction of LR/DM-risks is made possible.
- Subjects
RISK of metastasis; CANCER patients; CANCER patient medical care; CANCER relapse; COMBINED modality therapy; HISTOLOGY; PATIENT aftercare; MEDICAL cooperation; RADIOTHERAPY; REGRESSION analysis; RESEARCH; RISK assessment; SARCOMA; RETROSPECTIVE studies; STATISTICAL models; DESCRIPTIVE statistics; TUMOR grading; DISEASE risk factors
- Publication
Cancers, 2020, Vol 12, Issue 1, p47
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers12010047